All Stories

  1. Consideration and Application of Lipoprotein(a) in the Risk Assessment of Atherosclerotic Cardiovascular Disease Risk in Adults

    Article • CJC Open, November 2023, Elsevier

    Dr. Glen J. Pearson

  2. Explaining the TG cut-off in the 2021 lipid guidelines for when clinicians should rely on non-HDL-C or ApoB

    Article • Canadian Journal of Cardiology, November 2023, Elsevier

    Dr. Glen J. Pearson

  3. Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, April 2023, SAGE Publications

    Dr. Glen J. Pearson

  4. Ligne directrice C-CHANGE pour l’harmonisation des lignes directrices nationales de prévention et de prise en charge des maladies cardiovasculaires en contexte de soins primaires au Canada: mise à jour 2022

    Article • Canadian Medical Association Journal, January 2023, Canadian Medical Association (CMA)

    Dr. Glen J. Pearson

  5. Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update

    Article • Canadian Medical Association Journal, November 2022, Canadian Medical Association (CMA)

    Dr. Glen J. Pearson

  6. Omega-3 fatty acids for cardiovascular disease prevention: A practice tool for pharmacists

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, April 2022, SAGE Publications

    Dr. Glen J. Pearson

  7. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

    Article • Canadian Journal of Cardiology, August 2021, Elsevier

    Dr. Glen J. Pearson

  8. Lipid therapy: A new whiteboard video for patient education

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, April 2021, SAGE Publications

    Dr. Glen J. Pearson

  9. Association Between Hemoglobin A1c and Major Adverse Coronary Events in Patients with Diabetes Following Coronary Artery Bypass Surgery

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, January 2020, Wiley

    Dr. Glen J. Pearson

  10. Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization

    Article • CJC Open, November 2019, Elsevier

    Dr. Glen J. Pearson

  11. INTER PROFESSIONAL TEAM-BASED SYSTEMATIC EVALUATION AND MANAGEMENT OF LIPIDS IN CARDIAC REHABILITATION PATIENTS WITH CORONARY ARTERY DISEASE

    Article • Canadian Journal of Cardiology, October 2019, Elsevier

    Dr. Glen J. Pearson

  12. The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?

    Article • Canadian Journal of Cardiology, May 2019, Elsevier

    Dr. Glen J. Pearson

  13. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis

    Article • Annals of Pharmacotherapy, April 2019, SAGE Publications

    Dr. Glen J. Pearson

  14. Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial

    Article • Canadian Journal of Cardiology, December 2018, Elsevier

    Dr. Glen J. Pearson

  15. Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018

    Article • Canadian Journal of Cardiology, December 2018, Elsevier

    Dr. Glen J. Pearson

  16. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update

    Article • Canadian Medical Association Journal, October 2018, Canadian Medical Association (CMA)

    Dr. Glen J. Pearson

  17. Remote Pharmacist Practice Model of Collaboration in Primary Care

    Article • Circulation Cardiovascular Quality and Outcomes, June 2018, Wolters Kluwer Health

    Dr. Glen J. Pearson

  18. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events

    Article • American Journal of Health-System Pharmacy, May 2018, American Society of Health System Pharmacists

    Dr. Glen J. Pearson

  19. Prevention and management of statin adverse effects: A practical approach for pharmacists

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, April 2018, SAGE Publications

    Dr. Glen J. Pearson

  20. Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease

    Article • The American Journal of Cardiology, April 2018, Elsevier

    Dr. Glen J. Pearson

  21. Systematic review of the evidence for the use of DOAC's in patient with a heart transplant.

    Article • Transplantation Reviews, April 2018, Elsevier

    Dr. Glen J. Pearson

  22. Comment: Should an LDL Cholesterol Target–Based Approach Be Readopted?

    Article • Annals of Pharmacotherapy, March 2018, SAGE Publications

    Dr. Glen J. Pearson

  23. PHARMACOLOGICAL TREATMENT OF PATIENTS WITH ANGINA WITH NO OBSTRUCTIVE CORONARY ARTERY DISEASE (ANOCA): A SYSTEMATIC REVIEW

    Article • Canadian Journal of Cardiology, October 2017, Elsevier

    Dr. Glen J. Pearson

  24. The Past, the Present, and a Very Bright Future

    Article • The Canadian Journal of Hospital Pharmacy, August 2017, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  25. Dyslipidemia Treatment Guidelines

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, July 2017, SAGE Publications

    Dr. Glen J. Pearson

  26. La recherche de l’excellence en pratique professionnelle et l’obtention de la reconnaissance des pairs

    Article • The Canadian Journal of Hospital Pharmacy, March 2017, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  27. The Pursuit of Professional Practice Excellence and the Achievement of Peer Recognition

    Article • The Canadian Journal of Hospital Pharmacy, March 2017, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  28. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

    Article • Canadian Journal of Cardiology, November 2016, Elsevier

    Dr. Glen J. Pearson

  29. New Antilipid Drugs: Do the Known Benefits Justify the Expense?

    Article • The Canadian Journal of Hospital Pharmacy, August 2016, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  30. A randomized trial of a community-based approach to dyslipidemia management

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, August 2016, SAGE Publications

    Ross Tsuyuki, Dr. Glen J. Pearson

  31. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)

    Article • Canadian Journal of Cardiology, July 2016, Elsevier

    Dr. Glen J. Pearson

  32. Faire partie de la SCPH – un investissement dans votre avenir et celui de la pharmacie hospitalière!

    Article • The Canadian Journal of Hospital Pharmacy, April 2016, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  33. Belonging to CSHP—An Investment in Your Future and That of Hospital Pharmacy!

    Article • The Canadian Journal of Hospital Pharmacy, April 2016, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  34. Evaluation of the Management of Hyperlipidemia and Hypertension in an Outpatient Cardiac Transplant Clinic

    Article • Pharmacology &amp Pharmacy, January 2016, Scientific Research Publishing, Inc,

    Dr. Glen J. Pearson

  35. Death to the Print Format—But Let Us Not Forget Our Past

    Article • The Canadian Journal of Hospital Pharmacy, December 2015, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  36. Un changement de saison, un nouveau départ!

    Article • The Canadian Journal of Hospital Pharmacy, October 2015, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  37. A Change of Seasons—A New Beginning!

    Article • The Canadian Journal of Hospital Pharmacy, October 2015, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  38. Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection

    Article • The Journal of Heart and Lung Transplantation, May 2015, Elsevier

    Dr. Glen J. Pearson

  39. A New Year—Time for Reconciliation

    Article • The Canadian Journal of Hospital Pharmacy, February 2015, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  40. Une nouvelle année : l’heure est au bilan

    Article • The Canadian Journal of Hospital Pharmacy, February 2015, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  41. Professional Use of Social Media by Pharmacists

    Article • The Canadian Journal of Hospital Pharmacy, February 2015, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  42. Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, December 2014, SAGE Publications

    Dr. Glen J. Pearson

  43. Cardiovascular MRI Predicts 5-Year Adverse Clinical Outcome in Heart Transplant Recipients

    Article • American Journal of Transplantation, September 2014, Elsevier

    Dr. Glen J. Pearson

  44. L’art de la planification

    Article • The Canadian Journal of Hospital Pharmacy, August 2014, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  45. The Art of Planning

    Article • The Canadian Journal of Hospital Pharmacy, August 2014, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  46. Adverse drug reactions

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, June 2014, SAGE Publications

    Dr. Glen J. Pearson

  47. Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel

    Article • Canadian Journal of Cardiology, April 2014, Elsevier

    Dr. Glen J. Pearson

  48. Non-Immunosuppressant Medication Use in Heart Transplant Patients: A Guide for Pharmacists

    Article • Pharmacology &amp Pharmacy, January 2014, Scientific Research Publishing, Inc,

    Dr. Glen J. Pearson

  49. Evaluation of Preventive Cardiovascular Pharmacotherapy after Coronary Artery Bypass Graft Surgery

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, December 2013, Wiley

    Dr. Glen J. Pearson

  50. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update

    Article • Canadian Journal of Cardiology, December 2013, Elsevier

    Dr. Glen J. Pearson

  51. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

    Article • Canadian Journal of Cardiology, February 2013, Elsevier

    Dr. Glen J. Pearson

  52. An Evaluation of Teaching Physical Examination to Pharmacists

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, July 2012, SAGE Publications

    Dr. Glen J. Pearson

  53. An evaluation of teaching physical examination to pharmacists

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, June 2012, SAGE Publications

    Dr. Glen J. Pearson

  54. Research Grants from the CSHP Research and Education Foundation

    Article • The Canadian Journal of Hospital Pharmacy, April 2012, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  55. A Systematic Review of the Evidence for Pharmacist Care of Patients With Dyslipidemia

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, February 2012, Wiley

    Dr. Glen J. Pearson

  56. Frequency of Intensive Statin Therapy in Patients With Acute Coronary Syndrome Admitted to a Tertiary Care Center

    Article • The American Journal of Cardiology, January 2012, Elsevier

    Dr. Glen J. Pearson

  57. Secondary Stroke Prevention: Practice Patterns in a Tertiary Care Stroke Service

    Article • Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, March 2010, Cambridge University Press

    Dr. Glen J. Pearson

  58. Prescribing by Pharmacists and Collaborative Care: Are We Ready to Accept the Baton and Get in the Race?

    Article • The Canadian Journal of Hospital Pharmacy, February 2010, Canadian Society of Hospital Pharmacists (CSHP)

    Dr. Glen J. Pearson

  59. Making Hospital Pharmacists Indispensable on the Healthcare Team: Revolution in Waiting

    Article • Journal of Pharmacy Practice and Research, December 2009, Wiley

    Dr. Glen J. Pearson

  60. Colchicine for the Primary and Secondary Prevention of Pericarditis: An Update

    Article • Annals of Pharmacotherapy, November 2009, SAGE Publications

    Dr. Glen J. Pearson

  61. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations

    Article • Canadian Journal of Cardiology, October 2009, Elsevier

    Dr. Glen J. Pearson

  62. Impact of Pharmacist Interventions in Patients with Dyslipidemia: A Systematic Review

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, September 2009, SAGE Publications

    Dr. Glen J. Pearson

  63. Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients—a systematic review

    Article • Transplantation Reviews, July 2009, Elsevier

    Dr. Glen J. Pearson

  64. Macrolide Antibiotics and Calcineurin Inhibitors: Avoiding a Far too Common Drug Interaction in Transplant Patients

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, March 2009, SAGE Publications

    Dr. Glen J. Pearson

  65. Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease by Pharmacists

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, November 2008, SAGE Publications

    Dr. Glen J. Pearson

  66. Gaps, Goals and Getting to Target: A Call to Action for Pharmacists!

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, November 2008, SAGE Publications

    Dr. Glen J. Pearson

  67. Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience

    Article • Vascular Health and Risk Management, October 2008, Dove Medical Press

    Dr. Glen J. Pearson

  68. Optimizing Healthcare at the Population Level: Results of the Improving Cardiovascular Outcomes in Nova Scotia Partnership

    Article • Healthcare Quarterly, March 2008, Longwoods Publishing

    Dr. Glen J. Pearson

  69. 2007 guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists

    Article • Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, November 2007, SAGE Publications

    Dr. Glen J. Pearson

  70. Evolution in the practice of pharmacy--not a revolution!

    Article • Canadian Medical Association Journal, April 2007, Canadian Medical Association (CMA)

    Dr. Glen J. Pearson

  71. New advances in antirejection therapy

    Article • Current Opinion in Cardiology, March 2007, Wolters Kluwer Health

    Dr. Glen J. Pearson

  72. Clopidogrel-Precipitated Rhabdomyolysis in a Stable Heart Transplant Patient

    Article • Annals of Pharmacotherapy, January 2007, SAGE Publications

    Dr. Glen J. Pearson

  73. The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic

    Article • Canadian Journal of Cardiology, September 2006, Elsevier

    Dr. Glen J. Pearson

  74. Pretransplant Diabetes, Not Donor Age, Predicts Long-Term Outcomes in Cardiac Transplantation

    Article • Journal of Cardiac Surgery, March 2006, Wiley

    Dr. Glen J. Pearson

  75. Author's Reply

    Article • Annals of Pharmacotherapy, December 2005, SAGE Publications

    Dr. Glen J. Pearson

  76. Comment: supratherapeutic response to ezetimibe administered with cyclosporine

    Article • Annals of Pharmacotherapy, December 2005, SAGE Publications

    Dr. Glen J. Pearson

  77. Supratherapeutic Response to Ezetimibe Administered with Cyclosporine

    Article • Annals of Pharmacotherapy, September 2005, SAGE Publications

    Dr. Glen J. Pearson

  78. Long-Term Impact of a Community Pharmacist Intervention on Cholesterol Levels in Patients at High Risk for Cardiovascular Events: Extended Follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus)

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, January 2005, Wiley

    Dr. Glen J. Pearson

  79. Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?

    Article • Journal of Clinical Pharmacy and Therapeutics, August 2003, Wiley

    Dr. Glen J. Pearson

  80. Use of OTC and Herbal Products in Patients with Cardiovascular Disease

    Article • Annals of Pharmacotherapy, June 2003, SAGE Publications

    Dr. Glen J. Pearson

  81. The Importance of In-Hospital Statin Therapy for Patients with Acute Coronary Syndromes

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, April 2003, Wiley

    Dr. Glen J. Pearson

  82. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events

    Article • The American Journal of Cardiology, February 2002, Elsevier

    Dr. Glen J. Pearson

  83. Assessment of new onset postcoronary artery bypass surgery atrial fibrillation: current practice pattern review and the development of treatment guidelines

    Article • Journal of Clinical Pharmacy and Therapeutics, February 2002, Wiley

    Dr. Glen J. Pearson

  84. Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes

    Article • Journal of Clinical Pharmacy and Therapeutics, October 2001, Wiley

    Dr. Glen J. Pearson

  85. Case Report: I reatment of Blastomycosis with Fluconazole

    Article • The American Journal of the Medical Sciences, May 1992, Elsevier

    Dr. Glen J. Pearson